VJHemOnc is committed to improving our service to you

COMy 2019 | CyborD-DARA combination in first-line treatment for multiple myeloma

VJHemOnc is committed to improving our service to you

Michael O’Dwyer

Michael O’Dwyer, MD, PhD, from the National University of Ireland, Galway, Ireland, discusses the advantages of bringing daratumumab in the first-line setting as the CyborD-DARA combination ( cyclophosphamide, bortezomib and dexamethasone with daratumumab), for the treatment of multiple myeloma. Here, Prof. O’ Dwyer highlights that cyclophosphamide can activate macrophages, and therefore enhance antibody-dependent cellular phagocytosis. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter